Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra

Synapse

Volumn 65, Issue 11, 2011, Pages 1166-1172

  MacGillivray, L ^a   Reynolds, K B ^a   Sickand, M ^a   Rosebush, P I ^a   Mazurek, M F ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Citalopram; Fluoxetine; Microglia; Selective serotonin reuptake inhibitor; Serotonin transporter; Tyrosine hydroxylase

Indexed keywords

CITALOPRAM; DOPAMINE; FLUOXETINE; SEROTONIN TRANSPORTER; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CELL COUNT; CONTROLLED STUDY; DIETARY INTAKE; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MALE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TREATMENT DURATION;

ANIMALS; CITALOPRAM; DOPAMINERGIC NEURONS; DOWN-REGULATION; MALE; MICROGLIA; NEURAL INHIBITION; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA-BINDING PROTEINS; SEROTONIN UPTAKE INHIBITORS; SUBSTANTIA NIGRA;

EID: 80052355204     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20954     Document Type: Article

References (46)

1. Abercrombie M. 1946. Estimation of nuclear population from microtome sections. Anat Rec 94: 239-247.
2. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS. 1996. Akathisia: A review and case report following paroxetine treatment. Compr Psychiatry 37: 122-124.
3. Baldessarini RJ, Marsh E. 1990. Fluoxetine and side effects. Arch Gen Psychiatry 47: 191-192.
4. Boyer W. 1995. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 10: 45-49.
5. Brambilla P, Cipriani A, Hotopf M, Barbui C. 2005. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: A meta-analysis of clinical trial data. Pharmacopsychiatry 38: 69-77.
6. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD, Jr. 1993. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33: 512-517.
7. Caccia S, Cappi M, Fracasso C, Garattini S. 1990. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 100: 509-514.
8. Caley CF. 1997. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 31: 1481-1489.
9. Conrad LC, Leonard CM, Pfaff DW. 1974. Connections of the median and dorsal raphe nuclei in the rat: an autoradiographic and degeneration study. J Comp Neurol 156: 179-205.
10. Curti C, Mingatto FE, Polizello AC, Galastri LO, Uyemura SA, Santos AC. 1999. Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity. Mol Cell Biochem 199: 103-109.
11. Dray A, Davies J, Oakley NR, Tongroach P, Vellucci S. 1978. The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res 151: 431-442.
12. Dray A, Gonye TJ, Oakley NR, Tanner T. 1976. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res 113: 45-57.
13. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98: 14669-14674.
14. Fibiger HC, Miller JJ. 1977. An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 2: 975-987.
15. Fredricson Overo K. 1982a. Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 6: 311-318.
16. Fredricson Overo K. 1982b. Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuropsychopharmacol Biol Psychiatry 6: 297-309.
17. George MS, Trimble MR. 1993. Dystonic reaction associated with fluvoxamine. J Clin Psychopharmacol 13: 220-221.
18. Gerber PE, Lynd LD. 1998. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 32: 692-698.
19. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. 2006. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21: 404-412.
20. Ha E, Jung KH, Choe BK, Bae JH, Shin DH, Yim SV, Baik HH. 2006. Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells. Neurosci Lett 397: 185-189.
21. Hyttel J, Overo KF, Arnt J. 1984. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology (Berl) 83: 20-27.
22. James TA, Starr MS. 1980. Rotational behaviour elicited by 5-HT in the rat: evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum. J Pharm Pharmacol 32: 196-200.
23. Lambert MT, Trutia C, Petty F. 1998. Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 22: 741-748.
24. Leo RJ. 1996. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57: 449-454.
25. Levinson AJ, Garside S, Rosebush PI, Mazurek MF. 1998. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience 84: 201-211.
26. Marinova-Mutafchieva L, Sadeghian M, Broom L, Davis JB, Medhurst AD, Dexter DT. 2009. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J Neurochem 110: 966-975.
27. Maurer I, Moller HJ. 1997. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 174: 255-259.
28. Mazurek MF, Rosebush PI. 1996. Circadian pattern of acute, neuroleptic-induced dystonic reactions. Am J Psychiatry 153: 708-710.
29. McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
30. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC. 1979. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 45: 165-175.
31. Mirza B, Hadberg H, Thomsen P, Moos T. 2000. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95: 425-432.
32. Najjar F, Price LH. 2004. Citalopram and dystonia. J Am Acad Child Adolesc Psychiatry 43: 8-9.
33. Parker WD, Jr, Parks JK, Swerdlow RH. 2008. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 1189: 215-218.
34. Parvin MM, Swartz CM. 2005. Dystonic rabbit syndrome from citalopram. Clin Neuropharmacol 28: 289-291.
35. Pazos A, Probst A, Palacios JM. 1987. Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21: 123-139.
36. Pigott TA, Seay SM. 1999. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60: 101-106.
37. Przedborski S, Tieu K, Perier C, Vila M. 2004. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36: 375-379.
38. Rosebush PI, Mazurek MF. 1999. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 52: 782-785.
39. Schapira AH. 2010. Complex I: Inhibitors, inhibition and neurodegeneration. Exp Neurol 224: 331-335.
40. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. 2003. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341: 87-90.
41. Souza ME, Polizello AC, Uyemura SA, Castro-Silva O, Curti C. 1994. Effect of fluoxetine on rat liver mitochondria. Biochem Pharmacol 48: 535-541.
42. Steffens DC, Krishnan KR, Helms MJ. 1997. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6: 10-18.
43. Ugedo L, Grenhoff J, Svensson TH. 1989. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl) 98: 45-50.
44. Vaswani M, Linda FK, Ramesh S. 2003. Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27: 85-102.
45. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.
46. Zohar J, Westenberg HG. 2000. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403: 39-49.